Crinetics Pharmaceuticals

CRINETICS PHARMACEUTICALS SECOND QUARTER CONFERENCE CALL

August 8, 2024

Safe Harbor Statement

This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. ("Crinetics," the "company," "we," "us," or "our") cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: the strategic objectives for paltusotine; the plans and timelines for the clinical development of paltusotine, including the therapeutic potential and clinical benefits or safety profile thereof; the expected timing of the submission of a new drug application for paltusotine for the treatment of acromegaly and related open label extension studies and our plans to commercialize paltusotine; plans and timing for sharing the full results of the Phase 2 study of paltusotine in carcinoid syndrome with the FDA to align on a Phase 3 program and the plans and enrollment in related open label extension studies; the potential benefits of atumelnant (CRN04894) in patients with Congenital Adrenal Hyperplasia ("CAH") or Cushing's syndrome and the expected plans and timing for data and data readouts from ongoing clinical studies, including additional data from the Phase 2 study in Cushing's syndrome; plans and timing for sharing the full results of the Phase 2 study of atumelnant with the FDA to align on one or more Phase 3 programs; the plans and timelines for the clinical development of atumelnant, including the therapeutic potential and clinical benefits or safety profile thereof as well as our ability to commercialize atumelnant globally; the potential for any of our ongoing clinical studies to show safety or efficacy; the potential of our ongoing discovery efforts to target future indications for hyperparathyroidism, polycystic kidney disease, Graves diseases, thyroid eye disease, or diabetes/obesity, and the expected plans and timing for candidate selection and clinical development of such candidates; our plans to identify and create new drug candidates for additional diseases or the potential for any such new drug candidates to show safety or efficacy; the direction or trajectory of the Company's potential future growth, the Company's aims to establish a new medical standard for the treatment of acromegaly; the receipt of any revenues from product sales and the ability of such revenues to support continued growth, and our expected plans and timing for commercialization of paltusotine for acromegaly and carcinoid syndrome, atumelnant for CAH and Cushing's syndrome, and other product candidates pending clinal development, NDA submissions, and regulatory approval as applicable. In some cases, you can identify forward-looking statements by terms such as "may," "believe," "anticipate," "could," "should," "estimate," "expect," "intend," "plan," "project," "will," "contemplate," "predict," "continue," "forecast," "aspire," "lead to," "designed to," "goal," "aim," "potential," "target," or the negative of or other similar terms.

These statements speak only as of the date of this presentation, involve known and unknown risks, uncertainties, assumptions, and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, without limitation: topline and initial data that we report may change following a more comprehensive review of the data related to the clinical studies and such data may not accurately reflect the complete results of a clinical study, and the FDA and other regulatory authorities may not agree with our interpretation of such results; the risk that preliminary results of preclinical studies or clinical studies do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available, the possibility of unfavorable new clinical data and further analyses of existing clinical data; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the FDA or other regulatory agencies may require additional clinical studies of paltusotine in support of the approval of a New Drug Application or applicable foreign regulatory approval; international conflicts may disrupt our business and that of the third parties on which we depend, including delaying or otherwise disrupting our clinical studies and preclinical studies, manufacturing and supply chain, or impairing employee productivity; our dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; the success of our clinical studies, nonclinical studies and preclinical studies; regulatory developments or price restrictions in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval and/or commercialization; our ability to obtain and maintain intellectual property protection for our product candidates; we may use our capital resources sooner than we expect; and other risks described under the heading "Risk Factors" in documents we file from time to time with the Securities and Exchange Commission ("SEC"). Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and, except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Crinetics Pharmaceuticals

Building a **Premier Endocrine-focused** Pharmaceutical Company

Strategic Approach to **Growing Long-term Value**

Crinetics Pharmaceuticals

2Q2024 Highlights

Unprecedented atumelnant data for CAH and Cushing's disease shared at ENDO

Paltusotine patient-reported outcomes data shared at ENDO

Development candidates selected for hyperparathyroidism and ADPKD programs

Progress on regulatory milestones and preparation for paltusotine launch

CAH: Congenital adrenal hyperplasia; ADPKD: Autosomal dominant polycystic kidney disease.

Development and Regulatory Update

- **On track for submission of NDA for paltusotine in acromegaly in 2H2024**
- **Preparing to discuss paltusotine carcinoid syndrome Phase 3 plans with FDA**
- **Atumelnant CAH Phase 2 study fully enrolled with topline data expected in 2H2024**
- **On track to share additional data from atumelnant Phase 2 in Cushing's disease in 2H2024**

NDA: New drug application; CAH: Congenital adrenal hyperplasia.

Our Launch Strategy is to Establish a New Medical Standard of Care in the Treatment of Acromegaly

Partnering with Endocrinology Physician Community

Empowering Patients to Ask for Optimal Care

Ensuring Optimal Access to Therapy

Empower and engage with patients to convey that better care is possible in acromegaly

Crinetics Pharmaceuticals

Acro/Truth Disease Education





AcromegalyTruth.com

Crinetics Pharmaceuticals

Financial Highlights

(in millions)	Three months ended June 30, 2024	2023
Revenues	**$ 0.4**	**$ 1.0**
R&D Expenses	58.3	40.6
G&A Expenses	24.8	13.3
Net Loss	**$(74.1)**	**$(51.0)**

Cash and equivalents totaled **$863.0 million** as of June 30, 2024, sufficient to fund the company's current operating plan into 2028.

Crinetics Pharmaceuticals

Crinetics is Building the Premier Endocrine-focused Pharmaceutical Company



Continue to Expand and Advance Pipeline***

Hyperparathyroidism, Graves Disease & TED, Obesity, New Platforms

NDA: New drug application; CAH: Congenital adrenal hyperplasia; TED: Thyroid Eye Disease.
*Pending NDA submission, acceptance and regulatory approval. **Pending alignment with FDA on registrational studies, successful completion and NDA submission, acceptance and regulatory approval. ***Pending clinical development of new drug candidates for additional diseases

Crinetics Pharmaceuticals